Effects of incretin agonists on endothelial nitric oxide synthase expression and nitric oxide synthesis in human coronary artery endothelial cells exposed to TNFα and glycated albumin

Pharmacological Reports

Volumn 67, Issue 1, 2015, Pages 69-77

  Garczorz, Wojciech ^a   Francuz, Tomasz ^a   Siemianowicz, Krzysztof ^a   Kosowska, Agnieszka ^a   Kłych, Agnieszka ^a   Aghdam, Mohammad Reza F ^a   Jagoda, Krystyna ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Coronary artery endothelium; Glycated albumin; Incretin; Nitric oxide synthase; TNF

Indexed keywords

(4 AMINO 5 METHYLAMINO 2',7' DIFLUOROFLUORESCEIN)DIACETATE; ARGININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED ALBUMIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; REAGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; GLYCOSYLATED SERUM ALBUMIN; INCRETIN; NOS2 PROTEIN, HUMAN; NOS3 PROTEIN, HUMAN; ONCOPROTEIN; PEPTIDE; SERUM ALBUMIN; VENOM;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SYNTHESIS; AGONISTS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CORONARY BLOOD VESSEL; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

CORONARY VESSELS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; MAP KINASE SIGNALING SYSTEM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; ONCOGENE PROTEIN V-AKT; PEPTIDES; PHOSPHORYLATION; RNA, MESSENGER; SERUM ALBUMIN; TUMOR NECROSIS FACTOR-ALPHA; VENOMS;

EID: 84908628050     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2014.08.007     Document Type: Article

References (37)

1. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-41. http://dx.doi.org/10.1056/nejmoa1008862.
2. Phillips LK, Prins JB. Update on incretin hormones. Ann N Y Acad Sci 2011;1243(December):E55-74. http://dx.doi.org/10.1111/j.1749-6632.2012.06491.x. Review.
3. Sjöholm A. Impact of glucagon-like peptide-1 on endothelial function. Diabetes Obes Metab 2009;11(December (Suppl. 3)):19-25. http://dx.doi.org/10.1111/j.1463-1326.2009.01074.x. Review.
4. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004;287(December (6)):E1209-15 [Epub 2004 September 7].
5. Tanaka T, Nangaku M, Nishiyama A. The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors. Curr Opin Nephrol Hypertens 2011;20(September (5)):476-81. http://dx.doi.org/10.1097/MNH.0b013e328349af9d. Review.
6. Heo KS, Fujiwara K, Abe J. Glucagon-like peptide-1 and its cardiovascular effects. Curr Atheroscler Rep 2012;14(October (5)):422-8. http://dx.doi.org/10.1007/s11883-012-0265-9.
7. Liaudet L, Vassalli G, Pacher P. Role of peroxynitrite in the redox regulation of cell signal transduction pathways. Front Biosci 2009;14:4809-14.
8. Ding L, Zhang J. Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol Sin 2012;33(January (1)):75-81. http://dx.doi.org/10.1038/aps.2011.149 [Epub 2011 November 28].
9. Rafiee P, Johnson CP, Li MS, Ogawa H, Heidemann J, Fisher PJ, et al. Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS. Paradoxical proinflammatory effect on the microvascular endothelium. J Biol Chem 2002;277(September (38)):35605-15 [Epub 2002 July 10].
10. Yoshizumi M, Perrella MA, Burnett Jr JC, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993;73(July (1)):205-9.
11. Lu L, Pu LJ, Xu XW, Zhang Q, Zhang RY, Zhang JS, et al. Association of serum levels of glycated albumin, C-reactive protein and tumor necrosis factor-alpha with the severity of coronary artery disease and renal impairment in patients with type 2 diabetes mellitus. Clin Biochem 2007;40:810-6.
12. Furusyo N, Koga T, Ai M, Otokozawa S, Kohzuma T, Ikezaki H, et al. Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the Kyushu and Okinawa Population Study (KOPS). Diabetologia 2011;54(December (12)):3028-36. http://dx.doi.org/10.1007/s00125-011-2310-6 [Epub 2011 September 27].
13. Ma WY, Wu CC, Pei D, Hung KC, Hsia TL, Su CC, et al. Glycated albumin is independently associated with estimated glomerular filtration rate in nondiabetic patients with chronic kidney disease. Clin Chim Acta 2011;412(March (7-8)):583-6. http://dx.doi.org/10.1016/j.cca.2010.12.013 [Epub 2010 December 21].
14. Pu LJ, Lu L, Xu XW, Zhang RY, Zhang Q, Zhang JS, et al. Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2006;5(December):27.
15. Rodiño-Janeiro BK, González-Peteiro M, Ucieda-Somoza R, González-Juanatey JR, Alvarez E. Glycated albumin, a precursor of advanced glycation end-products, up-regulates NADPH oxidase and enhances oxidative stress in human endothelial cells: molecular correlate of diabetic vasculopathy. Diabetes Metab Res Rev 2010;26(October (7)):550-8. http://dx.doi.org/10.1002/dmrr.1117.
16. Baraka-Vidot J, Guerin-Dubourg A, Dubois F, Payet B, Bourdon E, Rondeau P. New insights into deleterious impacts of in vivo glycation on albumin antioxidant activities. Biochim Biophys Acta 2013;1830(June (6)):3532-41. http://dx.doi.org/10.1016/j.bbagen.2013.01.019 [Epub 2013 January 31].
17. Garczorz W, Francuz T, Gmiński J, Likus W, Siemianowicz K, Jurczak T, et al. Influence of elastin-derived peptides, glucose, LDL and oxLDL on nitric oxide synthase expression in human umbilical artery endothelial cells. Acta Biochim Pol 2011;58(3):375-9 [Epub 2011 July 11].
18. Havenga MJ, van Dam B, Groot BS, Grimbergen JM, Valerio D, Bout A, et al. Simultaneous detection of NOS-3 protein expression and nitric oxide production using a flow cytometer. Anal Biochem 2001;290(March (2)):283-91.
19. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. Horm Metab Res 2011;43(September (10)):731-4. http://dx.doi.org/10.1055/s-0031-1284383 [Epub 2011 September 19].
20. Sena CM, Pereira AM, Seic¸a R. Endothelial dysfunction - a major mediator of diabetic vascular disease. Biochim Biophys Acta 2013;1832(December (12)):2216-31. http://dx.doi.org/10.1016/j.bbadis.2013.08.006 [Epub 2013 August 29].
21. Cosentino F, Hishikawa K, Katusic ZS, Lüscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997;96(July (1)):25-8.
22. Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO. Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001;102(December (2-3)):81-6.
23. Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis 2013;226(February (2)):305-14. http://dx.doi.org/10.1016/j.atherosclerosis.2012.09.012 [Epub 2012 September 21, Review].
24. Nyström T, Gonon AT, Sjöholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005;125(February (1-3)):173-7.
25. Dong Z, Chai W, Wang W, Zhao L, Fu Z, Cao W, et al. Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitment. Am J Physiol Endocrinol Metab 2013;304(January (2)):E222-8. http://dx.doi.org/10.1152/ajpendo.00473.2012 [Epub 2012 November 27].
26. Erdogdu O, Nathanson D, Sjöholm A, Nyström T, Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 2010;325(August (1-2)):26-35. http://dx.doi.org/10.1016/j.mce.2010.04.022 [Epub 2010 May 7].
27. Böger RH. The pharmacodynamics of L-arginine. J Nutr 2007;137(June (6 Suppl. 2)):1650S-5S. Review.
28. Vilsbøll T, Brock B, Perrild H, Levin K, Lervang HH, Kølendorf K, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008;25(February (2)):152-6.
29. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and - independent pathways. Circulation 2008;117(May (18)):2340-50. http://dx.doi.org/10.1161/CIRCULATIONAHA.107.739938 [Epub 2008 April 21, Erratum in: Circulation. 2008 Jul 22;118(4):e81].
30. Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 2012;60(September (3)):833-41. http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.195115 [Epub Aug 6 2012].
31. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991;87(February (2)):432-8.
32. Lorber D. GLP-1 receptor agonists: effects on cardiovascular risk reduction. Cardiovasc Ther 2013;31(August (4)):238-49. http://dx.doi.org/10.1111/1755-5922.12000.
33. Dai Y, Mehta JL, Chen M. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation. Cardiovasc Drugs Ther 2013;27(October (5)):371-80. http://dx.doi.org/10.1007/s10557-013-6463-z.
34. Han L, Yu Y, Sun X, Wang B. Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK-eNOS pathways. Diabetes Res Clin Pract 2012;97(September (3)):453-60. http://dx.doi.org/10.1016/j.diabres.2012.04.001 [Epub May 5 2012].
35. Zhang H, Park Y, Wu J, Chen Xp, Lee S, Yang J, et al. Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond) 2009;116(February (3)):219-30. http://dx.doi.org/10.1042/CS20080196. Review.
36. Zheng Z, Li Z, Chen S, Pan J, Ma X. Tetramethylpyrazine attenuates TNF-α-induced iNOS expression in human endothelial cells: involvement of Syk-mediated activation of PI3K-IKK-IkB signaling pathways. Exp Cell Res 2013;319(August (14)):2145-51. http://dx.doi.org/10.1016/j.yexcr.2013.05.018 [Epub 2013 May 28].
37. Morikawa A, Koide N, Kato Y, Sugiyama T, Chakravortty D, Yoshida T, et al. Augmentation of nitric oxide production by gamma interferon in a mouse vascular endothelial cell line and its modulation by tumor necrosis factor alpha and lipopolysaccharide. Infect Immun 2000;68(November (11)):6209-14.